

**UNITED STATES SECURITIES AND EXCHANGE
COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF
SECURITIES**

OMB APPROVAL

OMB Number: 3235-0104

Estimated average burden
hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Thompson Travis Alvin</u> (Last) (First) (Middle) <u>C/O BICYCLE THERAPEUTICS PLC</u> <u>BLOCKS A & B, PORTWAY BUILDING</u> (Street) <u>CAMBRIDGE X0 CB21 6GS</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) <u>06/22/2023</u>	3. Issuer Name and Ticker or Trading Symbol <u>BICYCLE THERAPEUTICS plc [BCYC]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>Chief Accounting Officer</u>	5. If Amendment, Date of Original Filed (Month/Day/Year)
		6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person	

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares	8,094 ⁽¹⁾	D	

**Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Employee Stock Option (right to buy)	(2)	09/17/2028	Ordinary Shares	3,929	1.83 ⁽³⁾	D	
Employee Stock Option (right to buy)	(2)	04/24/2029	Ordinary Shares	456	8.03 ⁽³⁾	D	
Employee Stock Option (right to buy)	(4)	01/02/2030	Ordinary Shares	14,063	9.82	D	
Employee Stock Option (right to buy)	(5)	01/04/2031	Ordinary Shares	23,500	17.95	D	
Employee Stock Option (right to buy)	(6)	01/03/2032	Ordinary Shares	9,000	60.87	D	
Employee Stock Option (right to buy)	(7)	01/03/2033	Ordinary Shares	40,000	29.6	D	

Explanation of Responses:

1. Represents restricted stock unit ("RSU") awards. 3,094 RSUs shall vest in eleven equal quarterly installments commencing on July 3, 2023. 5,000 RSUs shall vest one-fourth (1/4) of the total number of RSUs on January 3, 2024, and the remaining RSUs shall vest in 12 equal quarterly installments thereafter.

2. Fully vested and exercisable.

3. This exercise price is in US Dollars and reflects the conversion of GBP to USD at an exchange rate of \$1.2605 to GBP 1.00 as of May 22, 2019.

4. This option vested one-fourth (1/4) of the total number of shares on January 2, 2021, and the remaining shares vested or shall vest in 36 equal monthly installments at the end of each calendar month thereafter.

5. This option vested one-fourth (1/4) of the total number of shares on January 4, 2022, and the remaining shares vested or shall vest in 36 equal monthly installments thereafter.

6. This option vested one-fourth (1/4) of the total number of shares on January 3, 2023, and the remaining shares vested or shall vest in 36 equal monthly installments thereafter.

7. This option shall vest one-fourth (1/4) of the total number of shares underlying the option on January 3, 2024, and the remaining shares vest in 36 equal monthly installments thereafter.

Remarks:

/s/ Jason Minio, Attorney-
in-Fact

07/03/2023

** Signature of Reporting
Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

(For Executing Form ID and Forms 3, 4 and 5)

Know all by these presents, that the undersigned hereby constitutes and appoints Kevin Lee of Bicycle Therapeutics plc (the "Company") and Laura Berezin, Jaime Chase, Dayne Brown and Jason Minio of Cooley LLP, signing individually, the undersigned's true and lawful attorneys-in fact and agents to:

(1) Prepare, execute in the undersigned's name and on the undersigned's behalf, and submit to the Securities and Exchange Commission (the "SEC"), a Form ID and Forms 3, 4 and 5 (including amendments thereto and joint filing agreements in connection therewith) in accordance with Section 16 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules thereunder, in the undersigned's capacity as an officer, director or beneficial owner of more than 10% of a registered class of securities of the Company;

(2) Do and perform any and all acts for and on behalf of the undersigned that may be necessary or desirable to prepare and execute any such Form ID and Forms 3, 4 or 5 (including amendments thereto and joint filing agreements in connection therewith) and file such forms with the SEC and any stock exchange, self-regulatory association or any similar authority; and

(3) Take any other action of any type whatsoever in connection with the foregoing that, in the opinion of such attorney-in-fact, may be of benefit to, in the best interest of, or legally required of the undersigned, it being understood that the documents executed by the attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney shall be in such form and shall contain such terms and conditions as the attorney-in-fact may approve in the attorney-in-fact's discretion.

The undersigned hereby grants to each such attorney in fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary, or proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney in fact, or such attorney in fact's substitute or substitutes, shall lawfully do or cause to be done by virtue of this power of attorney and the rights and powers herein granted. The undersigned acknowledges that the foregoing attorneys-in-fact, and their substitutes, in serving in such capacity at the request of the undersigned, are not assuming (nor is the Company assuming) any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act.

This Power of Attorney shall remain in full force and effect until the earliest to occur of (a) the undersigned is no longer required to file Forms 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, (b) revocation by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in fact or (c) as to any attorney-in-fact individually, until such attorney-in-fact is no longer employed by the Company or employed by or a partner at Cooley LLP or another law firm representing the Company, as applicable.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of the date written below.

Date: 6/29/2023
/s/ Travis Alvin Thompson
Travis Alvin Thompson